MRI-based 3D Hip Labrum and Cartilage Morphology in Patients With Hip Deformities Compared to Asymptomatic Volunteers
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Oct 17, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the shape and structure of the hip joint in people who do not have any hip pain (asymptomatic volunteers) and comparing it to those with hip deformities. Researchers will use a special type of MRI, which is a non-invasive imaging technique that does not involve any contrast dye, to take detailed pictures of the hip joint. By doing this, they hope to better understand how a healthy hip looks compared to one that has deformities.
To participate in the study, you need to be over 18 years old and have no significant hip pain or history of hip problems. You will also have to sign a consent form and pass a physical exam of your hip. If you have certain conditions, like being pregnant or having metal implants in your body, you may not be able to participate. If eligible, you can expect to undergo a painless MRI scan, which will help contribute to important research on hip health.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Age \> 18 years.
- • Signed an informed consent form.
- • History free of significant hip pain, with no history of juvenile hip disease, traumatic injuries, inflammatory conditions, or tumors affecting the hip.
- • Normal clinical examination of the hip.
- Exclusion Criteria:
- Individuals who are not considered suitable for MRI (Magnetic Resonance Imaging) for the following reasons:
- • Potential pregnancy
- • Presence of metal fragments in the eye or elsewhere in the body
- • Presence of implants and metallic foreign bodies, such as a pacemaker, heart valve, cerebrospinal fluid shunt, insulin pump, nerve stimulator, or cochlear implant
- • Claustrophobia
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Simon D. Steppacher, Dr.
Principal Investigator
University Hospital of Bern (Inselspital)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported